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Objective. To assess clinical progression and inﬂammatory markers among women stopping or continuing antiretroviral therapy
(ART)afterpregnancy.Methods.AR T -na ¨ ıvewomenwithCD4+lymphocytecounts>350cells/uLinitiatingARTduringpregnancy
had clinical events and laboratory markers compared over one year postpartum between those stopping (n = 59) or continuing
(n = 147) ART. Results. Slopes in CD4 count and HIV RNA did not diﬀer between groups overall and in subsets of ZDV or
combination therapy. The hazard ratio (HR) of a new class B event was 2.09 (95% CI 0.79–5.58) among women stopping ART,
1.24 (0.31–4.95) in those stopping ZDV, and 2.93 (0.64–13.36) among those stopping combination therapy. Women stopping
ART had increased immune activation. No signiﬁcant diﬀerences were seen in C-reactive protein, lipids, leptin, or interleukin-6.
Conclusions. While changes in CD4 and HIV RNA levels over one year were similar between women stopping or continuing ART
postpartum, higher immune activation among women stopping therapy requires further study.
Copyright © 2009 D. H. Watts et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Current guidelines recommend that pregnant women be
treated with highly active antiretroviral therapy (HAART)
regimens for prevention of perinatal transmission of HIV,
even if therapy is not yet recommended for treatment of
maternal HIV infection [1]. These therapies are generally
welltolerated during pregnancy [2] and have resulted in
rates of maternal-to-child transmission (MTCT) of under
2% among nonbreastfeeding populations [3]. Antiretroviral
therapy is often discontinued after delivery if prepregnancy
therapy was not indicated for maternal health [1].
Studies of scheduled treatment interruption showing
poorer outcomes among subjects randomized to treatment
interruption rather than continuous therapy have raised the
question of whether discontinuing therapy after delivery
among women receiving HAART for prevention of MTCT
may be harmful to the mother. Several small studies using
various treatment schedules have not suggested harm from
scheduled treatment interruptions, although all have shown
lower CD4+ lymphocyte counts at the end of the study
in treatment interruption groups [4–6]. Recently however,
results from other studies have shown higher rates of
morbidity and mortality among subjects assigned to a
treatment interruption arm compared to those provided
with continuous therapy. The CD4-guided therapy arm of
the Trivacan trial in Africa was stopped early because of
a signiﬁcantly increased rate of serious morbidity in the2 Infectious Diseases in Obstetrics and Gynecology
interruption arm (15.2/100 person-years) compared to the
continuous therapy arm (6.7/100 person-years, RR 2.27,
95% CI 1.15–4.76) [7]. At enrollment, all subjects had
CD4+ cell counts above 350cells/uL and HIV RNA below
300copies/mL. Therapy was reinstituted for a CD4 count
below 250cells/uL. The largest trial reported to date, the
SMART study, used similar inclusion and therapy inter-
ruption/reinstitution guidelines and included 5472 subjects
[8]. In SMART, the rate of opportunistic disease or death
was 3.3/100 person-years in the therapy interruption group
and 1.3/100 person-years in the continuous therapy group
(HR 2.6, 95% CI 1.9–3.7 for interruption compared to
continuous group). Unexpectedly, the hazard ratio for major
cardiovascular, renal, and hepatic disease was 1.7 (95% CI
1.1–2.5) for the interruption compared to the continuous
group, despite less overall antiretroviral drug exposure in the
interruption group.
While the results of TRIVACAN and SMART raise
concerns regarding the potential risk of stopping therapy
after use in pregnancy for prevention of perinatal trans-
mission, both of these trials used lower CD4+ lymphocyte
count thresholds for resumption of therapy than would
be used based on clinical treatment guidelines [9]. Data
on outcomes after antiretroviral therapy (ART) limited to
pregnancycomparedtosimilarwomennotreceivingtherapy
or continuing therapy are limited and primarily reﬂect use of
zidovudine (ZDV) monotherapy rather than HAART [10–
15]. Given the paucity of data on the long-term maternal
eﬀects of short-term HAART regimens for prevention of
perinatal transmission of HIV and the concerns regarding
therapy interruption raised by the SMART and TrivAcan
studies, we compared clinical and laboratory outcomes after
delivery among women enrolled to the Women and Infants
Transmission Study (WITS), a longitudinal cohort study,
who either stopped or continued antiretroviral therapy at
delivery that had been started for prevention of MTCT of
HIV.Laboratorymarkersofimmuneactivationandpotential
cardiovascular and metabolic risk were included.
2. Methods
WITS is a multicenter prospective observational study of
pregnant women and their infants [16]. Beginning in
December (1989), pregnant HIV-1-infected women were
recruited at centers in Chicago, Massachusetts (Boston and
Worcester), New York City, and San Juan. Sites were added
in Brooklyn in 1991 and in Houston in 1993. The study
was approved by each site’s Institutional Review Board, and
all women provided informed consent for enrollment of
themselves and their infants. Women were enrolled during
pregnancy or within 7 days after delivery, and infants were
enrolled within 7 days of birth. For women monitored
duringpregnancy,studyvisitsoccurredatorbefore20weeks’
gestation, at 25 ± 2w e e k s ,a t3 2± 2 weeks, and at delivery.
Women were followed for one year after delivery with visits
at two, six, and twelve months. At each visit, a detailed
medical and behavioral questionnaire was administered, and
a physical examination and phlebotomy were performed.
Additional data on women and infants were obtained from
medical record abstraction.
Antiretroviral treatment was not prescribed as part of
the study but detailed data on its use was collected. Therapy
during pregnancy was categorized as ZDV monotherapy or
combination therapy, consisting of at least two nucleoside
reverse transcriptase inhibitors with or without nonnucle-
oside reverse transcriptase inhibitors or protease inhibitors.
Clinical events were categorized using the 1993 CDC revised
surveillance case deﬁnition [17].
To be eligible for inclusion in this analysis, women had to
be enrolled after 6/1/1994 when use of ZDV for prevention
of HIV transmission became standard therapy for pregnant
women and before 6/30/2006 to allow a year of followup
postpartum. In addition, they had to be enrolled by 32 weeks
of gestation to allow time for antiretroviral therapy to be
administrated and be ART na¨ ıve at enrollment. They had
to have a CD4+ lymphocyte count above 350cells/uL at
enrollment so that ART was being prescribed primarily for
preventionofMTCTandnotformaternalhealthindications.
Ofthe3297womenenrolledtoWITSby6/30/2006,2777had
a conﬁrmed delivery, 1165 were ART na¨ ıve at enrollment,
and 1091 of these were enrolled before the delivery visit. Of
these, 512 received ART during pregnancy, 261 of whom had
a CD4+ lymphocyte count above 350cells/uL at enrollment
during pregnancy, and 206 were enrolled after 6/1/1994. The
206 women included did not diﬀer signiﬁcantly from the
3091 women not included in age, race/ethnicity, history of
CDC class B or C condition, or HIV RNA levels. Based
on inclusion criteria, included women had higher CD4+
lymphocyte counts (mean 603cells/uL versus 467cells/uL,
P<. 001)andlowergestationalageatenrollment(16.1weeks
versus 21.6 weeks, P<. 001) than the excluded women.
To assess HIV disease progression, we used knotted
splines and mixed eﬀect models to compare the post
delivery slope of the CD4+ lymphocyte counts, CD4+
lymphocyte percents, and HIV RNA levels between women
continuing or stopping ART at delivery using [18, 19]. Rates
of development of new CDC class B or C events were
compared using Cox proportional hazard models [20]. The
marginal mean values for laboratory testing postpartum
were compared between the above listed groups using a
generalestimatingequation[19].Whenindicated,somedata
were log-transformed to produce a normal distribution.
CD4+ lymphocyte counts were determined by ﬂow
cytometry at DAIDS Immunology Quality Assurance Pro-
gram certiﬁed laboratories. Lymphocyte phenotyping was
done using a FACScan (Becton Dickinson, San Jose, CA)
equipped with LYSIS II software as previously described
[21]. Plasma HIV-1 RNA was measured in stored specimens
using the Roche Amplicor HIV-1 Monitor Test (Roche
Diagnostic Systems, Branchburg, NJ), as described in [22].
Specimens were assayed for routine metabolic analytes (total
cholesterol, high-density lipoprotein (HDL) cholesterol,
triglycerides, high sensitivity C-reactive protein (hsCRP)) at
Quest Diagnostics, Baltimore, MD and for specialty analytes
(leptin,lipoprotein-associatedphospholipaseA2(Lp-PLA2),
interleukin 6 (IL-6)) at Quest Diagnostics Nichols Institute,
San Juan Capistrano, CA. Aliquots of frozen serum wereInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Baseline characteristics of women included in the study according to status of antiretroviral therapy after delivery.
Characteristic Total n = 206 Stopped therapy n = 59 Continued therapy n = 147 P∗
Race/ethnicity .43
White 22 (10.7%) 8 (13.6%) 14 (9.5%)
African American 98 (47.6%) 29 (49.2%) 69 (46.9%)
Latina 75 (36.4%) 21 (35.6%) 54 (36.7%)
Other 11 (5.3%) 1 (1.7%) 10 (6.8%)
CD4+ lymphocyte count .03
350–500cells/uL 84 (40.9%) 17 (28.8%) 67 (45.6%)
>500cells/uL 122 (59.2%) 42 (71.2%) 80 (54.4%)
CDC Classiﬁed events
Class B or worse 59 (28.6%) 15 (25.4%) 44 (29.9%) .52∗∗
Class C 6 (2.9%) 2 (3.4%) 4 (2.7%) .80∗∗
Mean enrollment CD4+ lymphocyte count 603 680.3 ±63.9 572.5 ±30.5 .004
Mean enrollment CD4+ percentage 34.2% ± 1.93 1 .8% ±1.4. 0 6
Mean gestational age (weeks) 16.1 16.1 ±1.91 6 .1 ±1.2. 9 7
Mean enrollment HIV RNA (log10) 2.63 ±0.53 .00 ±0.3. 2 3
Mean maternal age 25.9 ±1.22 7 .7 ±1.0. 0 4
Therapy during pregnancy
Zidovudine monotherapy
∧ 103 (50%) 41 (40%) 62 (60%)
Combination therapy 100 (49%) 18 (18%) 82 (82%)
∗ T test comparing means or proportions except as noted. ∗∗ Chi square test used. ∧ Three additional women received monotherapy with other agents, one
with nevirapine and two with didanosine.
shipped to Quest Diagnostics on dry ice for batch testing of
each analyte. Low-density lipoprotein cholesterol (LDL) was
calculated using the Friedewald Equation for those samples
exhibiting triglyceride values below 400mg/dL. The labora-
tory utilized the FDA-cleared Cholesterol Esterase/Oxidase
method of Olympus (Olympus America, Inc., Melville, NY)
on an automated testing platform for total cholesterol quan-
titation. For HDL cholesterol, the laboratory utilized the
FDA-cleared, HDL-Cholesterol Plus 2nd Generation assay
from Roche Diagnostics (Indianapolis, IN) on an automated
testing platform. For triglyceride quantitation, the labo-
ratory utilized the FDA-cleared Triglyceride reagents from
Olympus on an automated testing platform. Serum high
sensitivity CRP levels were measured using the FDA-cleared,
automated BN II in vitro diagnostic system (Dade Behring,
Inc., Newark, DE). This method uses a particle enhanced
immunonephelometric assay with a sensitivity of 0.2mg/L.
Leptin was measured using the Research Use Only Human
Leptin RIA Kit from Linco Research, Inc. (St. Charles Mis-
souri). This method is a competitive radioimmunoassay that
utilizes a ﬁxed concentration of Iodine-125-labeled human
leptin tracer antigen with a constant dilution of human
leptin antiserum. The concentration of unknown human
leptin in the study subject’s samples is determined against
a calibration curve that is set up with each assay run that
includes increasing concentrations of standard unlabeled
human leptin antigen. Human IL-6 was measured with the
Research Use Only Quantikine HS Human IL-6 Immunoas-
say kit from R&D Systems, Inc. (Minneapolis, MN). This
assay utilizes a quantitative sandwich enzyme immunoassay
technique to estimate the concentration of IL-6 in serum
specimens. Lp-PLA2 was measured with the FDA-approved
PLAC test kit from diaDexus (South San Francisco, CA).
3. Results
Of the 206 women eligible for inclusion, 147 continued
therapy after delivery and 59 discontinued. A comparison
of the two groups is shown in Table 1. Women stopping
therapy at delivery were slightly younger and had higher
CD4+ lymphocyte counts than women continuing therapy,
but the groups were similar in race/ethnicity, gestational age
at enrollment, history of class B or C illness, and HIV RNA
levels.
ZDV monotherapy was used by 103 women during
pregnancy, 41 of whom stopped therapy at delivery, and
62 of whom continued. Three additional women received
monotherapy with other drugs, one with nevirapine and
two with didanosine. One hundred women took two or
more antiretroviral drugs during pregnancy, 18 of whom
stopped therapy at delivery, and 82 of whom continued. Of
thewomenoncombinationtherapy,27tooktwoNRTI’s,two
took triple NRTI regimens including abacavir, 11 took two
NRTI’splusanNNRTI,55tooktwoNRTI’swithoneormore
PI’s, four took triple class regimens, and one took a regimen
of one NRTI with an NNRTI.
We compared the risk of HIV disease progression
between women who stopped and women who continued
therapy after delivery in several ways. The slopes of CD4+
lymphocyte counts and percentages and of HIV RNA levels
were compared between two and six months and six and
twelve months postpartum to assess for “rebound changes”4 Infectious Diseases in Obstetrics and Gynecology
after stopping therapy. As shown in Figure 1 and Table 2, the
rate of change in CD4+ cell measures and HIV RNA was not
signiﬁcantly diﬀerent between the two groups. To evaluate
further by type of therapy during pregnancy, the changes in
CD4+ lymphocyte count and percentage and HIV RNA level
were compared among those stopping or continuing ZDV
monotherapyandthosestoppingorcontinuingcombination
regimens. Table 2 shows the diﬀerence in slope for each
parameter between all women who stopped or continued
therapy, women who stopped or continued ZDV monother-
apy, and those who continued or stopped combination
therapy. For example, over two to six months after delivery,
women in the entire group who stopped therapy had a
12.2cells/month loss in CD4+ lymphocyte count compared
to women continuing therapy, but the diﬀerence was not
signiﬁcant. No signiﬁcant diﬀerences between slopes were
found for any of the time periods or any of the therapy
groups.
Clinical progression was also assessed. None of the
women developed a new class C condition during the ﬁrst
year postpartum. Among the entire group, the hazard ratio
(HR) for development of a new class B condition was 2.09
(95% CI 0.79–5.58, P = .1 4 )f o rw o m e nw h os t o p p e d
therapy at delivery compared to those who continued. For
the ZDV monotherapy group, the HR was 1.24 (95% CI
0.31–4.95, P = .76) and for the combination therapy group
theHRwas2.93(95%CI0.64–13.36,P = .16).ClassBevents
among women stopping therapy included cervical dyspla-
sia/carcinoma in situ (CIS) in four, recurrent pneumonia
in one, and vaginal yeast infection for over 28 days in one.
Class B events among women continuing therapy included
cervical dysplasia/CIS in three, oropharyngeal candidiasis
in two, other infections in two, and other gastrointestinal
problem, vaginal yeast infection for over 28 days, and pelvic
inﬂammatory disease in one each.
Since treatment interruption studies have suggested an
increased risk of morbidity not speciﬁcally related to HIV
disease progression, we evaluated several laboratory markers
of immune activation and of potentially increased risk of
cardiovascular disease (Table 3). CD4+ and CD8+ counts
and percentages are shown for all women in the analysis
and each subgroup. Lymphocyte activation markers were
available for a subset of women. Of note, the CD8+CD38+ T
lymphocyte and CD8+DR+ T lymphocyte percentages were
higher in women stopping therapy than in those continuing
in the overall group and the ZDV group. Results were
available in too few women in the combination therapy
group to allow meaningful analyses. HS-CRP, lipid levels,
leptin, and interleukin-6 levels were not diﬀerent between
the groups among all women and those receiving ZDV. Lp-
PLA2 levels were signiﬁcantly diﬀerent in the total group and
the combination therapy group, but levels were higher in the
women continuing therapy compared to those stopping.
4. Discussion
Overall, the data on changes in CD4+ lymphocyte count,
HIV RNA levels, and clinical progression are reassuring
over the ﬁrst year postpartum among women with CD4+
550
650
750
850
950
M
e
a
n
C
D
4
c
o
u
n
t
2 4 6 8 10 12
Followup visits postpartum (months)
Comparing slopes, P = .51 for 2–6 mos, .46 for 6–12 mos.
(a)
25
30
35
40
M
e
a
n
C
D
4
p
e
r
c
e
n
t
(
%
)
2 4 6 8 10 12
Followup visits postpartum (months)
Comparing slopes, P = .96 for 2–6 mos, .46 for 6–12 mos.
ART group
Pre+ and post−
Pre+ and post+
(b)
2
3
4
5
M
e
a
n
l
o
g
R
N
A
2 4 6 8 10 12
Followup visits postpartum (months)
Comparing slopes, P = .35 for 2–6 mos, .43 for 6–12 mos.
ART group
Pre+ and post−
Pre+ and post+
(c)
Figure 1: Changes in (a) CD4+ lymphocyte count, (b) CD4+
lymphocyte percentage, and (c) HIV RNA levels between two
months and 12 months after delivery among all women (regardless
of antiretroviral regimen) stopping (dashed line) or continuing
(solid line) antiretroviral therapy after delivery.Infectious Diseases in Obstetrics and Gynecology 5
Table 2: Diﬀerence in slope and P-values between women stopping or continuing therapy after delivery, according to antiretroviral therapy
use during pregnancy.
All women ZDV monotherapy Combination therapy
Parameter 2–6 months 6–12 months 2–6 months Parameter 2–6 months 6–12 months
CD4 count −12.2, P = .51 10.0, P = .46 −19.5, P = .52 CD4 count −12.2, P = .51 10.0, P = .46
CD4+ % −0.01, P = .96 −0.13, P = .46 0.06, P = .82 CD4+ % −0.01, P = .96 −0.13, P = .46
Log10 HIV RNA −0.07, P = .35 −0.04, P = .43 −0.10, P = .25 Log10 HIV RNA −0.07, P = .35 −0.04, P = .43
Table 3: Median postpartum laboratory values among women continuing or stopping antiretroviral therapy postpartum according to
therapy during pregnancy.
All women ZDV monotherapy Combination therapy
Parameter +/- +/+ P +/- +/+ p +/- +/+ P
CD4+ lymphocyte count 733.2 701.7 .47 725.2 711.0 .84 754 690.5 .33
CD4+ lymphocyte % 34.8 33.9 .42 34.2 32.6 .31 36.3 34.9 .44
CD8+ lymphocyte count 935.1 949.9 .81 985.3 1042.8 .56 818.4 874.0 .48
CD8+ lymphocyte % 44.7 44.7 .98 46.4 48.1 .41 40.8 41.9 .67
CD19+ % 9.0 9.6 .72 9.6 8.9 .72
CD8+CD57+ % 17.3 16.6 .80 18.8 18.8 .99
CD8+DR+ % 36.3 26.6 .02 35.9 24.9 .01
CD16+CD56+ % 4.8 7.4 .04 5.2 7.8 .12
CD8+CD38+ % 47.6 36.7 .001 49.8 40.5 .04
High sensitivity C-reactive protein (mg/L) 2.8 3.0 .69 2.7 3.1 .58
Cholesterol (mg/dL) 177.7 188.7 .10 177.7 188.7 .11
High density lipoprotein (mg/dL) 47.8 49.3 .56 48.1 49.2 .67
Low density lipoprotein (mg/dL) 95.6 101.5 .30 94.6 100.5 .35
Triglycerides (mg/dL) 180.0 184.7 .81 181.0 187.1 .77
Leptin (ng/dL) 21.0 19.3 .54 20.1 19.7 .90
Interleukin-6 (pg/dL) 1.9 1.6 .22 2.2 1.7 .33 1.7 1.6 .65
Lipoprotein phospholipase A-2 (ng/dL) 166.1 187.0 .05 170.6 188.5 .37 161.3 185.5 .05
+/- indicates women who stopped therapy at delivery; +/+ indicates women who continued therapy after delivery. Postpartum specimens were collected at
six to 12 months postpartum.
lymphocyte counts above 350cells/uL who choose to stop
antiretroviral therapy after delivery compared to those who
continue.Onerecentretrospectivereviewfoundanincreased
risk of death or opportunistic infection among women
stopping therapy after delivery, but the group was more
heterogeneous than in the current study with 46% having
previous ARV exposure and 36% having a pre-ARV CD4+
cell count below 350cells/uL [15]. The number of Class B
events in our study was low for both the continuation and
noncontinuation groups, making it diﬃcult to further deﬁne
the risk of developing these events according to treatment
continuation. The relative risk estimate for combination
therapy is consistent with other studies and is consistent
with changes in activated CD8+ counts and percents that
was seen in this study. However, when taken in the context
of the overall low numbers of events, and insigniﬁcant
changes in CD4+ count and CD8+ count slopes there is
little evidence that stopping therapy increases a woman’s risk
of progression. Among those enrolled to the SMART study,
divergenceofthecurves intherisk ofopportunistic infection
or death were seen by 12 months after enrollment between
the drug conservation and viral suppression groups, even
among those who were therapy na¨ ıve or not on antiretroviral
therapy at delivery [8, 23]. However, women included in
the current study were all therapy na¨ ıve with nadir CD4+
lymphocyte counts above 350cells/uL and baseline CD4+
cell counts of 603cells/uL, compared to the SMART study
in which the median nadir CD4+ lymphocyte count was
250cells/uL and participants had initiated antiretroviral
therapy a median of six years before enrollment [8]. Among
subjects in SMART who were antiretroviral na¨ ıve, the nadir
CD4+ lymphocyte count was 376cells/uL and the baseline
was 437cells/uL, also lower than in the current study [23].
Thus, diﬀerences in disease progression in those stopping
therapy compared to those continuing may take longer to
manifest among women with higher baseline CD4+ cell
counts and no prior antiretroviral therapy.
A concerning laboratory ﬁnding between the groups
was higher levels of CD8+ cell activation among women
stopping therapy at delivery compared to those continuing.
Pregnancy has been shown to lead to increased levels of
CD8+DR+CD38+ lymphocytes in HIV-uninfected women
compared to nonpregnant women, but levels return to
baseline after delivery [21, 24] ,w h i l el e v e l sa r em u c h6 Infectious Diseases in Obstetrics and Gynecology
higherduringpregnancyinHIV-infectedwomenandremain
elevated postpartum in the absence of antiretroviral therapy
[21]. The current data suggest that continuing antiretroviral
therapy after pregnancy may reduce levels of CD8+ cell
activation among HIV-infected women overall and among
women on ZDV compared to women who stop therapy, but
lymphocyte activation results were available for only two
women stopping combination regimens, precluding a com-
parison in this group. Increased levels of CD8+DR+CD38+
cells have been associated with both an increased risk of
disease progression [25] and reduced CD4+ cell gains on
HAART [26]. Thus persistently high levels postpartum may
predict more rapid disease progression over time in those
stopping therapy, but longer followup is required to assess
thishypothesis.Inaddition,lymphocyteactivationshouldbe
comparedbetweenwomenstopping andcontinuing HAART
regimens after delivery in larger numbers of women.
Elevated hsCRP has recently been shown to predict HIV
disease progression among untreated HIV-infected women
postpartum [27]. We did not observe signiﬁcant diﬀerences
in CRP levels between women stopping versus continuing
therapy postpartum, suggesting against diﬀerential risk in
disease progression.
One of the areas of increased morbidity and mortal-
ity noted in subjects in the drug conservation group of
the SMART trial was cardiovascular outcomes including
myocardial infarction, coronary artery disease requiring
surgery, and stroke [8]. Since the median age in the SMART
trial was 43 years compared to 27 years in the current
study, we evaluated surrogate markers of cardiovascular risk
sincecardiovasculareventswerenotexpected.Medianvalues
of laboratory markers that have been associated with an
increasedriskofcardiovascularoutcomes,includingelevated
cholesterol, low density lipoproteins, triglycerides, and high
sensitivity C-reactive protein, and decreased high density
lipoproteins were not diﬀerent between groups continuing
versus stopping therapy. These results do not suggest an
increased risk of cardiovascular morbidity among women
stopping therapy but the predictive value of these markers
in HIV-infected populations has primarily been assessed in
populations of older men [28], and gender diﬀerences have
been noted in some analytes in the general population [29].
The only analyte found to diﬀer between the groups was
LP-PLA2, a macrophage-derived enzyme that has been an
independent predictor of cardiovascular events in healthy
populations [30, 31]. Lp-PLA2 is not an acute phase reactant
andisonlyminimallycorrelatedwithsystemicinﬂammatory
and hemostatic markers, suggesting that it may be useful
for prediction of cardiovascular risk in HIV-infected groups,
although further study is required [31]. Of note, Lp-
PLA2 levels were higher among women continuing therapy,
possibly indicating higher risk associated with continued
ART exposure or possibly related to the older age. The
median values in both groups were lower than the proposed
cutoﬀ of below 235ng/mL, so the clinical implications of the
diﬀerences require further study. The overall results however
do not suggest a major diﬀerence in cardiovascular risk
between the groups, and especially not increased risk among
women stopping therapy.
While the SMART study clearly showed beneﬁts to
continuing ART once initiated, not all STI studies have
shown diﬀerences in outcome. Negative studies had smaller
sample sizes but also used higher thresholds for restarting
ART. Studies using a threshold of 350cells/uL for reinitiating
ART tended to show fewer diﬀerences in outcomes between
continuous versus interrupted therapy [4–6]. These studies
are more consistent with the current standard of care in
developing countries, with initiation of therapy recom-
mended at a CD4+ cell count of 350cells/uL, which would
apply to pregnant women stopping ART used for prevention
of PMTCT. In developing countries, therapy is usually
initiated at a lower CD4+ cell count of 200–250cells/uL,
more similar to the situation in the SMART study. In
addition, if studies currently in progress conﬁrm reduced
transmission with maternal HAART during breastfeeding,
women in developing countries may have longer periods of
HAART for prevention of PMTCT before discontinuation,
potentially increasing the risk of adverse outcomes with
discontinuation. Assessment of the eﬀects of discontinuing
ARTusedforPMTCTmustbeincludedinstudiesinresource
limited settings.
The current results are generally reassuring that stopping
ART used solely for PMTCT does not increase the short-
term risk of HIV disease progression or of abnormalities
in common cardiovascular risk markers. However, followup
was only for one year postpartum, and longer followup
may be needed to detect diﬀerences in this relatively healthy
population [15]. Women were not randomized, but chose
whether or not to continue therapy in consultation with
their health care provider. Thus, there may be unmeasured
confounders that aﬀected the outcomes and mitigated
diﬀerences. Finally, the numbers included in this study were
relatively low, especially in the group stopping combination
therapy, thus limiting power.
5. Conclusions
Overall, the data do not indicate major diﬀerences in short-
t e r mo u t c o m eb e t w e e nw o m e nw i t hC D 4 +c e l lc o u n t sa b o v e
350cells/uL who choose to stop or continue ART that was
initiated for PMTCT. However, declines in lymphocyte acti-
vation markers among women continuing ART are consis-
tent with large treatment interruption studies demonstrating
improved outcomes with continuous rather than intermit-
tent ART. As use of combined ART regimens for prevention
of PMTCT expands, especially in developing countries
where thresholds for reinitiation of therapy are lower and
duration of preventive therapy may be longer if used during
breastfeeding,furtherevaluation,inrandomizedtrials,ofthe
risks and beneﬁts of continuing therapy, is required.
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